GT Biopharma, Inc. (GTBP) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for GT Biopharma, Inc. (GTBP:NASDAQ), powered by AI.
- Current Price
- $0.43
- Sector
- Healthcare
What is the GT Biopharma, Inc. stock price forecast?
GT Biopharma, Inc. is currently trading at $0.43. View real-time AI analysis on Alpha Lenz.
What is GT Biopharma, Inc. insider trading activity?
View the latest insider trading data for GT Biopharma, Inc. on Alpha Lenz.
What is GT Biopharma, Inc.'s P/E ratio?
View GT Biopharma, Inc.'s valuation metrics on Alpha Lenz.
GT Biopharma, Inc.
NASDAQ · GTBP“GT Biopharma, Inc.'s ROE is -1377.4%. Explore profitability and growth together.”
Ask for details →Company Overview
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapies. It utilizes proprietary platforms to create novel drugs targeting a range of cancers, including acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple solid tumors. The company is particularly noted for its TriKE (Tri-specific Killer Engager) platform, which represents a significant advancement in immuno-oncology treatments. By specializing in these therapeutic areas, GT Biopharma, Inc. plays a critical role in the healthcare sector, particularly within the biotechnology industry. Its products aim to improve treatment outcomes for patients with cancer, contributing to medical advancements and shaping the future of cancer therapy.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“GT Biopharma, Inc.'s ROE is -1377.4%. Explore profitability and growth together.”
Ask for details →Frequently Asked Questions
GT Biopharma, Inc. (ticker: GTBP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 1 employees.
The current price is $0.434 with a P/E ratio of -x and P/B of -x.
ROE is -1377.41%.